Introduction: The aim of this study was to investigate whether Cortexin®, a brain peptide-containing agent, has any mitigating effect on high glucose-induced neuropathy, using primary cultured rat sensory neurons. Materials and Methods: Dorsal root ganglia (DRG) were excised from decapitated adult rats. Individual neurons were isolated following enzymatic and mechanical procedures. Cells were seeded on E-plate® with gold microelectrodes and maintained in conventional culture media in a CO2 incubator at 37°C. After allowing for 24 h for cell adhesion and recovery from acute enzymatic trauma, neurons were exposed to high glucose (HpG) in the absence and presence of different concentrations of Cortexin® (2–40 µg/mL). Neuroprotective effects were followed with the Real-Time Cell Analyzer® by utilizing measurement of Cell Index, a parameter representing cell viability, cell attachment, and neurite outgrowth. Results: Exposure of DRGs to HpG (50 m<sc>m</sc>) caused a rapid and sustained decrease in the mean area under the curve (AUC, values derived from time vs. Cell Index curve) compared to the mean AUC values in normoglycemic (NG) wells. Co-treatment with Cortexin® attenuated this HpG-induced effect, in a concentration-dependent manner (NG: 1.00 ± 0.00 vs. HG: 0.18 ± 0.02, p < 0.05; and HpG + Cortexin® [40 µg/mL]: 0.66 ± 0.17, p = 0.002 versus HpG). In normoglycemic conditions, Cortexin® treatment led to a concentration-dependent increase in the mean AUC values. Conclusions: Data from this in vitro study suggest that Cortexin® has potential neuroprotective effects against chronic hyperglycemic insult in rat sensory neurons. Our results warrant further in vivo studies and may have clinical implications for diabetes-associated peripheral neuropathy.

1.
Hammi
C
,
Yeung
B
.
Neuropathy
. [Updated 2022 Oct 15]. In:
StatPearls
Treasure Island (FL)
StatPearls Publishing
2022 Jan
. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542220/.
2.
Deli
G
,
Bosnyak
E
,
Pusch
G
,
Komoly
S
,
Feher
G
.
Diabetic neuropathies: diagnosis and management
.
Neuroendocrinology
.
2013
;
98
(
4
):
267
80
.
3.
Melli
G
,
Höke
A
.
Dorsal root ganglia sensory neuronal cultures: a tool for drug discovery for peripheral neuropathies
.
Expert Opin Drug Discov
.
2009
;
4
(
10
):
1035
45
.
4.
Lehmann
HC
,
Staff
NP
,
Hoke
A
.
Modeling chemotherapy induced peripheral neuropathy (CIPN) in vitro: prospects and limitations
.
Exp Neurol
.
2020
;
326
:
113140
.
5.
Feldman
EL
,
Callaghan
BC
,
Pop-Busui
R
,
Zochodne
DW
,
Wright
DE
,
Bennett
DL
.
Diabetic neuropathy
.
Nat Rev Dis Primers
.
2019
;
5
(
1
):
42
.
6.
Riss
TL
,
Moravec
RA
.
Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays
.
Assay Drug Dev Technol
.
2004
;
2
(
1
):
51
62
.
7.
Halim
AB
.
Do We have a satisfactory cell viability assay? Review of the currently commercially-available assays
.
Curr Drug Discov Technol
.
2020
;
17
(
1
):
2
22
.
8.
Franke
R
,
Hinkelmann
B
,
Fetz
V
,
Stradal
T
,
Sasse
F
,
Klawonn
F
.
xCELLanalyzer: a Framework for the analysis of cellular impedance measurements for mode of action discovery
.
SLAS Discov
.
2019
;
24
(
3
):
213
23
.
9.
Ke
N
,
Wang
X
,
Xu
X
,
Abassi
YA
.
The xCELLigence system for real-time and label-free monitoring of cell viability
.
Methods Mol Biol
.
2011
;
740
:
33
43
.
10.
Solov’ev
AG
,
Elistratova
TV
.
[Effectiveness of cortexin in the complex treatment of patients with chronic alcohol encephalopathy and polyneuropathy]
.
Zh Nevrol Psikhiatr Im S S Korsakova
.
2010
;
110
(
4
):
48
51
.
11.
Yakovlev
AA
,
Lyzhin
AA
,
Khaspekov
LG
,
Guekht
AB
,
Gulyaeva
NV
.
Peptidnyĭ preparat korteksin ingibiruet kaspazu-8 mozga [Peptide drug cortexin inhibits brain caspase-8]
.
Biomed Khim
.
2017
;
63
(
1
):
27
31
.
12.
Zhang
H
,
Li
N
,
Li
Z
,
Li
Y
,
Yu
Y
,
Zhang
L
.
The involvement of caspases in neuroinflammation and neuronal apoptosis in chronic pain and potential therapeutic targets
.
Front Pharmacol
.
2022
;
13
:
898574
.
13.
Kleman
AM
,
Yuan
JY
,
Aja
S
,
Ronnett
GV
,
Landree
LE
.
Physiological glucose is critical for optimized neuronal viability and AMPK responsiveness in vitro
.
J Neurosci Methods
.
2008
;
167
(
2
):
292
301
.
14.
Russell
JW
,
Sullivan
KA
,
Windebank
AJ
,
Herrmann
DN
,
Feldman
EL
.
Neurons undergo apoptosis in animal and cell culture models of diabetes
.
Neurobiol Dis
.
1999
;
6
(
5
):
347
63
.
15.
Sango
K
,
Saito
H
,
Takano
M
,
Tokashiki
A
,
Inoue
S
,
Horie
H
.
Cultured adult animal neurons and schwann cells give us new insights into diabetic neuropathy
.
Curr Diabetes Rev
.
2006
;
2
:
169
83
.
16.
Kurkin
DV
,
Bakulin
DA
,
Morkovin
EI
,
Kalatanova
AV
,
Makarenko
IE
,
Dorotenko
AR
.
Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats
.
PLoS One
.
2021
;
16
(
7
):
e0254493
.
17.
Apfel
SC
.
Neurotrophic factors and diabetic peripheral neuropathy
.
Eur Neurol
.
1999
41
Suppl 1
27
34
.
18.
Kilinç
F
,
Colak
R
,
Ozcan
R
,
Ayar
A
.
Investigation of effects of neurotrophic factors on painful diabetic neuropathy: an experimental study
.
Eur Res J
.
2019
;
5
:
641
8
.
19.
Qureshi
Z
,
Ali
MN
,
Khalid
M
.
An insight into potential pharmacotherapeutic agents for painful diabetic neuropathy
.
J Diabetes Res
.
2022
;
2022
:
9989272
.
20.
Madonna
R
,
Görbe
A
,
Ferdinandy
P
,
De Caterina
R
.
Glucose metabolism, hyperosmotic stress, and reprogramming of somatic cells
.
Mol Biotechnol
.
2013
;
55
(
2
):
169
78
.
21.
Madonna
R
,
Geng
YJ
,
Shelat
H
,
Ferdinandy
P
,
De Caterina
R
.
High glucose-induced hyperosmolarity impacts proliferation, cytoskeleton remodeling and migration of human induced pluripotent stem cells via aquaporin-1
.
Biochim Biophys Acta
.
2014
;
1842
(
11
):
2266
75
.
22.
Levchuk
LA
,
Ivanova
SA
,
Semke
VY
.
Effects of neuroprotector cortexin on the dynamics of neuroendocrine system parameters in patients with organic emotionally labile (asthenic) disorders
.
Bull Exp Biol Med
.
2013
;
155
(
1
):
75
7
.
23.
Fedin
AI
,
Belskaya
GN
,
Kurushina
OV
,
Kovalchuk
VV
,
Starych
EV
,
Chichanovskaya
LV
.
[Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)]
.
Z Nevrol Psikhiatr Im S S Korsakova
.
2018
;
118
(
9
):
35
42
.
24.
Albrecht
W
.
Which concentrations are optimal for in vitro testing
.
EXCLI J
.
2020
;
19
:
1172
3
.
You do not currently have access to this content.